Utility of VEGF and sVEGFR-1 in Bronchoalveolar Lavage Fluid for Differential Diagnosis of Primary Lung Cancer |
Cao, Chao
(Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Sun, Shi-Fang (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University) Lv, Dan (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University) Chen, Zhong-Bo (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University) Ding, Qun-Li (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University) Deng, Zai-Chun (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University) |
1 | Bugdayci G, Kaplan T, Sezer S, et al (2006). Matrix metalloproteinase-9 in broncho-alveolar lavage fluid of patients with non-small cell lung cancer. Exp Oncol, 28, 169-71. |
2 | Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8. |
3 | Charalabopoulos K, Karakosta A, Bablekos G, et al (2007). CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers. Med Oncol, 24, 219-25. DOI ScienceOn |
4 | Cremades MJ, Men ndez R, Pastor A, Llopis R, Aznar J (1998). Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med, 92, 766-71. DOI ScienceOn |
5 | Denizot Y, Leguyader A, Cornu E, et al (2007). Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. J Cardiothorac Surg, 2, 38. DOI ScienceOn |
6 | Domaga_a-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R (2006). Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp, 54, 143-7. DOI ScienceOn |
7 | Ellis JR, Gleeson FV (2001). Lung cancer screening. Br J Radiol, 74, 478-85. DOI |
8 | Emad A, Emad V (2008). The value of BAL fluid LDH level in differentiating benign from malignant solitary pulmonary nodules. J Cancer Res Clin Oncol, 134, 489-93. DOI |
9 | Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2, 795-803. DOI ScienceOn |
10 | Ferrara N, Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev, 18, 4-25. DOI ScienceOn |
11 | Fiorelli A, Morgillo F, Fasano M, et al (2013). The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. Interact Cardiovasc Thorac Surg, 16, 263-9. DOI |
12 | Hooper CE, Elvers KT, Welsh GI, Millar AB, Maskell NA (2012). VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes. Lung Cancer, 77, 443-9. DOI ScienceOn |
13 | Ilhan N, Ilhan N, Deveci F (2004). Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem, 37, 840-5. DOI ScienceOn |
14 | Karahalli E, Yilmaz A, T rker H, Ozvaran K (2001). Usefulness of various diagnostic techniques during fiberoptic bronchoscopy of endoscopically visible lung cancer: should cytologic examinations be performed routinely. Respiration, 68, 611-4. DOI ScienceOn |
15 | Kishiro I, Kato S, Fuse D, Yoshida T, Machida S, Kaneko N (2002). Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology, 7, 93-8. DOI ScienceOn |
16 | Marcus PM (2001).Lung cancer screening: an update. J Clin Oncol, 19, S83-6. |
17 | Mazzone P, Jain P, Arroliga AC, Matthay RA (2002). Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med, 23, 137-58. DOI |
18 | Ohta Y, Ohta N, Tamura M, et al (2002). Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest, 121, 1624-7. DOI ScienceOn |
19 | Shibuya M (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-and Pro-Angiogenic Therapies. Genes Cancer, 2, 1097-105. DOI ScienceOn |
20 | Sun SF, Huang DB, Cao C, Deng ZC (2013). Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population. Med Oncol, 30, 410. DOI ScienceOn |
21 | Swidzi_ska E, Ossoli_ska M, Naumnik W, et al (2004). Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer. Pneumonol Alergol Pol, 72, 389-94. |
22 | Tamura M, Ohta Y, Nakamura H, Oda M, Watanabe G (2002). Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers, 17, 275-9. |
23 | Wang Z, Chen Y, Li X, et al (2012). Expression of VEGF-C/ VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. Asian Pac J Cancer Prev, 13, 27-31. DOI ScienceOn |
24 | Wingo PA, Ries LA, Giovino GA, et al (1999). Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst, 91, 675-90. DOI ScienceOn |